Dr. Dayton Dennis Payne Jr., MD

Dr. Payne practices at Piedmont Rheumatology, P.a. in Hickory, North Carolina.

Dr. Payne's NPI, 1639121239, was assigned on May 16, 2006. Dr. Payne graduated from West Virginia University School Of Medicine in 1987. Dr. Payne holds North Carolina license 35459.

Dr. Payne's primary practice is Piedmont Rheumatology, P.a., at 225 18th St Se, Hickory, NC 28602-1364. The practice phone is (828) 322-1996.

Dr. Payne's primary practice is Piedmont Rheumatology, P.a. in Hickory, North Carolina. Dr. Payne is also affiliated with Catawba Valley Medical Center. The medical group on file is Piedmont Rheumatology. Dmand AI also links Dr. Payne to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Payne practices, 3 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Payne's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Payne is board certified in rheumatology by the American Board of Internal Medicine. Dmand AI has Dr. Payne's licenses on file in 3 states: North Carolina, Illinois and West Virginia.

Dmand AI lists arteritis, arthritis, fibromyalgia and chronic pain, gout, joint arthropathy, joint pain, lupus and muscle pain, fibromyalgia, and limb pain among the conditions Dr. Payne treats.

CMS data shows 129,615 Medicare services from Dr. Payne across 16 procedure codes in 2024, for 339 Medicare patients. Medicare paid $1,127,947 for them. Every service was in an office.

CMS counts 339 Medicare patients who saw Dr. Payne in 2024. The largest group is 65 to 74, with 153 patients. 75% of them have arthritis, and 75% have high blood pressure. 8% are also on Medicaid. Their average risk score is 1.39, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Payne's median patient age at 70, with 76% women.

In 2024, Dr. Payne wrote 9,389 Medicare Part D claims for 765 patients. 91% of them were for generic drugs. CMS names the drug for 9,021 of them, across 92 drugs with 11 or more claims each, at $4,883,015 in total drug cost. In 2023, CMS named 8,447 claims across 94 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Payne for performance year 2024, reported as part of a group. Dr. Payne accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Payne to 5 clinical trials, 3 of them phase 3 studies. Conditions studied include Rheumatic Diseases, Arthritis, Rheumatoid and Gout. Open Payments lists research payments to Dr. Payne that name 1 trial.

CMS Open Payments shows 746 general payments to Dr. Payne from 40 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 92% of the total. Amgen Inc. paid the most, $2,433. It also lists 2 research payments totaling $797 from 2019 to 2022, naming 1 clinical trial.

Dmand AI lists 1 award for Dr. Payne, most recently CMS Stage 1 EHR in 2013.

Dr. Payne graduated from West Virginia University School Of Medicine in 1987.

Dr. Payne is in network with 15 carriers, including Aetna, United Healthcare and Blue Cross and Blue Shield of North Carolina. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.